Triflusal

Overview

Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and the increase of cyclic nucleotide concentration on endothelial cells. The latest translates into the expansion of peripheral blood vessels. It is very important as a secondary prevention of ischemic stroke by offering a lower risk of bleeding. It was developed by J. Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.

Indication

Triflusal is indicated as prophylaxis of thromboembolic disorders. It has been registered in Spain and in other countries of Europe, South America and South Korea for the prevention of Stroke and myocardial infarction.

Associated Conditions

Thromboembolism
Arterial thromboembolic disease

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress	2016/09/16	NCT02904109	Phase 2	Completed	Prof. Dominique de Quervain, MD
ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)	2015/11/30	NCT02616497	Phase 4	Completed	University of Ioannina
Influence of Triflusal on Cognitive Functions in Healthy Subjects	2014/12/22	NCT02321852	Phase 2	Completed	Prof. Dominique de Quervain, MD
The Effect of Triflusal on Peripheral Microcirculation Dysfunction	2012/06/05	NCT01612273	Phase 4	Completed	Yonsei University
Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping	2010/08/04	NCT01174693	Phase 4	Completed	Gangnam Severance Hospital
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity	2005/09/13	NCT00162799	Phase 2	Completed	J. Uriach and Company

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
TRIFLUSAL STADA 300 mg CAPSULAS EFG	Laboratorio Stada S.L.	65249	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Not Commercialized
TRIFLUSAL RATIOPHARM 300 mg CAPSULAS EFG	Teva Pharma S.L.U.	65268	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Not Commercialized
DISGREN 600 mg POLVO Y DISOLVENTE PARA SOLUCION ORAL	Laboratorios Ern S.A.	68135	POLVO Y DISOLVENTE PARA SOLUCIÓN ORAL	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Not Commercialized
DISGREN 300 MG CÁPSULAS DURAS	Laboratorios Ern S.A.	55295	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Commercialized
TRIFLUSAL TEVA 300 mg CAPSULAS EFG	Teva Pharma S.L.U.	68092	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Not Commercialized
TRIFLUSAL FARMALIDER 300 mg CAPSULAS DURAS EFG	Farmalider S.A.	65247	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Not Commercialized
ANPEVAL 300 mg CAPSULAS DURAS EFG	Industria Quimica Y Farmaceutica Vir S.A.	65248	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Commercialized
TRIFLUSAL ARISTO 300 mg CAPSULAS EFG	Aristo Pharma Iberia S.L.	66104	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Not Commercialized
TRIFLUSAL ABAMED 300 MG CAPSULAS EFG	Qualix Pharma S.L.	65246	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Commercialized
TRIFLUSAL PENSA 300 mg CAPSULAS DURAS EFG	Towa Pharmaceutical S.A.	76110	CÁPSULA DURA	Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access